There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intellia Therapeutics (NTLA) and TransMedics Group (TMDX) with bullish sentiments.
Intellia Therapeutics (NTLA)
In a report released yesterday, Steven Seedhouse from Raymond James maintained a Buy rating on Intellia Therapeutics, with a price target of $106.00. The company’s shares closed last Tuesday at $78.98.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 7.9% and a 47.4% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.
Intellia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $85.89, representing a 7.8% upside. In a report issued on May 28, Evercore ISI also maintained a Buy rating on the stock with a $90.00 price target.
See today’s analyst top recommended stocks >>
TransMedics Group (TMDX)
In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group, with a price target of $49.00. The company’s shares closed last Tuesday at $26.43.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 8.9% and a 57.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
Currently, the analyst consensus on TransMedics Group is a Strong Buy with an average price target of $53.00, implying a 99.2% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $79.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.